Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
11,381 total articles
An activist investor pushing a 'Year of Efficiency' gives Snap a credible path to higher margins and cash flow. At a $8.3B market cap with positive free cash flow and reasonable price-to-sales, the setup looks actionable. We lay out an entry, stop, targets and a balanced risk framework tied to litigation and ad-market cyclicality.
United Therapeutics' second positive TETON outcome for nebulized Tyvaso plus encouraging ralinepag data clears a runway of regulatory catalysts and upside. The balance sheet and recurring revenue base justify a continued 'Strong Buy' stance. This trade idea lays out an actionable entry at the current level, a protective stop, and a target tied to r…
Joby is trading near $8.28 with a market cap around $8.1B, a strong cash position ($4.01B) and a recent Type Inspection Authorization flight. With FAA progress and manufacturing scale plans, the risk/reward looks attractive for a disciplined long trade targeting $14.00, while limiting downside with a $6.00 stop.
Sportradar’s recent deal flow, margin expansion and select institutional buying argue the company is moving from growth-only to quality growth. At $16.64 the stock is trading well below its 52-week high but still at a premium multiple; this trade idea targets a re-rating catalyzed by product integrations and rights wins while respecting execution a…
Cadre Holdings dropped sharply from recent highs amid a broad defense-stock meltdown. Fundamentals - including $56.8M in free cash flow, a healthy current ratio and manageable leverage - argue the pullback is an opportunity. I upgrade CDRE to Strong Buy for a mid-term swing: enter $31.72, stop $28.00, target $42.00 (45 trading days).
Freshworks is trading near the low end of its 52-week range after a year of volatility. The stock now carries a sub-$2.3B market cap, positive free cash flow ($236.7M), and a P/E in the low-teens — metrics that look attractive relative to the company's 16% reported revenue growth and cleaner profitability. We upgrade to a Tactical Buy and lay out a…
Lamb Weston (LW) has been punished after an ERP-related sales disruption and softer pricing, but underlying cash flow, reasonable valuation and improving technicals suggest fiscal Q3 weakness could be the low-risk entry for a mid-term rebound. This is a swing trade idea with entry, stop and target defined and a clear risk framework.
Microsoft's pullback has created a high-quality, lower-risk entry for disciplined buyers. With a fortress balance sheet, $77.4B of free cash flow and a trailing EPS of $16.06, I upgrade MSFT to a Buy on a plan to accumulate at 22x earnings ($353.32). The trade targets a recovery back toward the $440 area over the next 180 trading days while protect…
Argan reported a clean Q4 earnings beat driven by margin expansion and an outsized backlog tied to data-center and power projects. The stock has power behind it - a near-zero debt profile, strong free cash flow, and technical momentum - but it trades at a premium. This trade idea lays out a mid-term (45 trading days) entry, stop and target, plus th…
Micron sold off after headlines about Google's TurboQuant and a volatile market swing, but core demand for high-bandwidth memory (HBM) and a rising capital plan keep the story intact. Fundamentals - strong cash flow, expanding capex to capture AI demand, and earnings power - combined with a 3:1+ reward-to-risk on this setup argue for a tactical lon…
We upgrade Abbott Laboratories (ABT) to Buy ahead of Q1 results. At $103.52, the shares trade below near-term averages with a PE ~27.6, a healthy dividend yield (~2.3%), and strong free cash flow ($7.4B). Recent weakness centers on diagnostics and nutrition, but medical devices growth, a manageable balance sheet (debt/equity 0.25), and the $21B Exa…
Lumentum is squarely in the middle of an optical upgrade cycle for AI data centers. With an S&P 500 addition, a $2 billion strategic allocation from NVIDIA, and accelerating revenue and earnings prints, LITE has momentum. Valuation is rich, so the trade is a tactical long with a defined stop and multi-horizon targets.
Unity Bancorp (UNTY) delivered record 2025 earnings, double-digit loan and deposit growth and a tidy return on equity, yet it trades at about 9x earnings and 1.5x book. That combination of earnings momentum, attractive multiples and benign technicals supports a tactical long. This trade sets an entry near current levels, a disciplined stop, and a t…
CRISPR Therapeutics (CRSP) looks to be at a commercial turning point as Casgevy patient initiations and early sales accelerate. With a $2.33B cash cushion, multiple pipeline readouts ahead and heavy short interest amplifying volatility, this trade idea targets asymmetric upside while protecting capital with a strict stop. Entry $49.75, target $68.0…
Costamare looks protected in the immediate window thanks to contract coverage, a steady dividend and balance-sheet metrics that keep downside limited. At the same time, six newbuilds, cyclical freight-rate risk and a stretched market multiple relative to shipping volatility argue for caution over the next 1-3 months. The trade: buy the bounce now f…
Lyft trades at a steep discount to implied intrinsic value given $1.12B in free cash flow, EPS of $7.14 and an enterprise value roughly equal to market cap. Combine that with a clear pathway to margin expansion and robotaxi upside and you have an asymmetric risk-reward. Enter $13.41, target $20.00, stop $11.00 for a long-term trade over 180 trading…
Visa (V) is a high-return payments franchise trading below many short-term technical levels but still supported by exceptional free cash flow, a 43% ROE and manageable leverage. The pullback—down from a $375.51 52-week high to around $300—creates a tactical long opportunity for disciplined traders looking for asymmetric reward-to-risk over the next…
nCino has shown durable booking strength and is converting growth into free cash flow. At a market cap near $1.92B and FCF of roughly $59.7M, valuation is stretched but not extreme for a SaaS fintech with improving margins. I upgrade to a buy for a position trade with an entry at $16.79, a stop at $14.30 and a primary target of $26.00 (180 trading …
EQB’s acquisition of PC Financial assets meaningfully accelerates deposit growth and lending scale. Credit-quality noise is real, but the structural benefits to funding, margin and franchise value provide a clearer path to upside. This trade idea lays out an actionable long with entry, stop and targets over a 180-trading-day horizon.
Snap’s stock popped into the $4.80s after activist noise and short-covering. Fundamentals show an $8.16B market cap, positive free cash flow, and modest valuation vs. prior highs. Against legal overhang and competition, this presents a defined-risk, high-reward swing trade opportunity.
Quanta Services (PWR) sits squarely in front of a generational U.S. reindustrialization and data center power cycle. The company’s $44B backlog, diverse end markets, and strong free cash flow profile justify a tactical upgrade. This trade idea outlines a long trade with clear entry, stop, and target while laying out the valuation framing, catalysts…
Laureate Education ($LAUR) looks like a value compounder trading at sensible multiples after a strong enrollment-driven recovery and a renewed $100M repurchase program. With a market cap near $5.05B, free cash flow of $263.1M and an EV/EBITDA of 9.8, we set a long-term trade targeting $45 while protecting capital with a $30 stop.
Achieve Life Sciences (ACHV) has been punished over the past months despite an approaching FDA review for cytisinicline. The sell-off, heavy short interest and compressed technicals have created an asymmetric risk/reward for disciplined longs who can tolerate binary regulatory risk. This trade plan defines entry, stop and target with a 180-trading-…
Nvidia's announced $2 billion investment and strategic partnership with Marvell transforms Marvell from a fast-growing networking and storage ASIC vendor into a core partner for hyperscale AI infrastructure. With data-center revenue up 21% year-over-year and management guiding revenue to roughly $11 billion, Marvell has the growth profile and cash …
Abivax (ABVX) remains a compelling long idea. Obefazimod's differentiated data package, emerging anti-fibrotic signal and concentrated asset base create strategic scarcity that magnifies upside from a successful Phase 3 maintenance readout in Q2 2026 or a takeover bid. We maintain Buy: enter at $117.65, target $150.00, stop $95.00. Trade horizon: l…
